NeoGenomics Reports Revenue of $25.1 Million and Record Adjusted EBITDA of $2.8 Million Driven by a 25% Increase in Test Volume in the Third Quarter of 2015
Go back to NeoGenomics Reports Revenue of $25.1 Million and Record Adjusted EBITDA of $2.8 Million Driven by a 25% Increase in Test Volume in the Third Quarter of 2015| NEOGENOMICS (NASDAQ: NEO) | Delayed: 11.20 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $11.20 | 52 Week High | $9.54 | |||
| Open | $11.20 | 52 Week Low | $5.49 | |||
| Day High | $11.20 | P/E | 280.00 | |||
| Day Low | $11.20 | EPS | $0.04 | |||
| Volume | 24,835 | |||||
